Male contraceptives market seen reaching $15.2 billion by 2030

The Business Research Company says the global male contraceptives market is on track to keep expanding through 2030, driven by rising awareness of reproductive health, new product technologies and more shared decision-making among men. The market is expected to rise from $10.46 billion in 2025 to $11.25 billion in 2026 before reaching $15.2 billion by 2030.

Why it matters: - The male contraceptives market is expanding as family planning becomes a more shared responsibility and demand grows for safer, more reversible options. - Growth in this category affects contraceptive access, reproductive health counseling and drug development priorities. - The report points to rising interest in non-hormonal methods, telehealth support and advanced condom materials as signals of where the market is heading.

What happened: - The Business Research Company released a male contraceptives market research report with forecasts through 2030. - The market is projected to grow from $10.46 billion in 2025 to $11.25 billion in 2026, a 7.6% compound annual growth rate. - The report forecasts the market will reach $15.2 billion by 2030, growing at a 7.8% CAGR. - The company made a free sample report available. - The company also published the full male contraceptives market report.

The details: - Male contraceptives include medical products and interventions designed to prevent pregnancy by temporarily or permanently regulating male fertility. - These methods work by reducing sperm production, impairing sperm mobility and function, or blocking sperm delivery. - Market growth in 2026 is tied to family planning awareness, routine condom use for pregnancy and STI prevention, pharmaceutical research on reproductive hormone regulation, government population-control initiatives and efforts to curb sexually transmitted diseases. - The forecast through 2030 is supported by reversible male contraceptive methods, implant technologies, non-hormonal sperm inhibition therapies, regulatory approvals for drug candidates and AI-powered drug discovery. - The report says more men are taking part in contraceptive decision-making. - Key trends include demand for safer non-hormonal contraceptives, clinical trials focused on long-term efficacy, improved condom materials and telehealth services for reproductive health counseling.

Between the lines: - The report frames awareness of male reproductive health as a major demand driver, not just product innovation. - In July 2025, the Local Government Association in the UK reported that more than 2.74 million people accessed sexual health clinics in England during 2023, with men accounting for more than 60% of new STI diagnoses. - That data suggests reproductive health education and STI prevention remain important market supports, especially for methods with broader public-health value. - North America was the dominant regional market in 2025, while Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa.

What's next: - The report says future market growth will depend on continued innovation in non-hormonal and reversible contraceptive options. - More clinical trial activity and regulatory approvals could expand the pipeline of male contraceptive drug candidates. - Wider use of telehealth and reproductive counseling may improve adoption as consumer awareness rises. - The report also adds new 2026 features, including market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables.

The bottom line: - Male contraceptives are moving from a narrow product category to a broader reproductive-health market with stronger technology, research and consumer demand behind it.